ISHITADR
Ishita Drugs & Industries financials
- Market cap
- ₹23 Cr
Quarterly results
Q1 FY27: revenue down 41.7%, net profit down 23.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 4 | 5 | 5 | 3 −6% | 3 −24% | 3 −33% | 3 −42% |
| EBITDA | 0 | 0 | 0 | 0 | 0 −25% | 0 −53% | 0 −66% | 0 −9% |
| Net profit | 0 | 0 | 0 | 0 | 0 −26% | 0 −33% | 0 −38% | 0 −23% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −1.7% 1Y
1Y: ₹75.25 on 9 Sept 2025 → ₹74. High ₹84.11 (25 Sept 2025), low ₹67.6 (6 Mar 2026).
Financials, as filed
Revenue fell 1.8% a year over 2 years, FY24 to FY26. Operating margin narrowed to 5.2%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹15 Cr | ₹15 Cr | ₹15 Cr |
| Operating profit | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Operating margin | 6.1% | 6.7% | 5.2% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Net margin | 4.9% | 5.8% | 5.3% |
| Cash from operations | ₹2 Cr | ₹-4 Cr | ₹4 Cr |
| Free cash flow | ₹2 Cr | ₹-4 Cr | ₹2 Cr |
| ROCE | 10.8% | 9.9% | 8.7% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
| Reserves | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹8 Cr | ₹9 Cr |
| Borrowings | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹2 Cr | ₹0 Cr |
| Other liabilities | ₹1 Cr | ₹3 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Total liabilities | ₹9 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹15 Cr | ₹13 Cr |
| Fixed assets | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹2 Cr |
| Investments | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹6 Cr | ₹4 Cr |
| Other assets | ₹5 Cr | ₹6 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹6 Cr |
| Total assets | ₹9 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹15 Cr | ₹13 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public trimmed −0.13 pp while promoters added +0.12 pp. The shareholder count shrank 4% to 5,146.
- Promoters
- 50.0%
- Public
- 50.0%
Since Jun 2025
- Public −0.13 pp
- Promoters +0.12 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 49.4%, Public 50.6%.Dec '23: Promoters 49.4%, Public 50.6%.Mar '24: Promoters 49.4%, Public 50.6%.Jun '24: Promoters 49.8%, Public 50.2%.Sep '24: Promoters 49.8%, Public 50.2%.Dec '24: Promoters 49.9%, Public 50.1%.Mar '25: Promoters 49.9%, Public 50.1%.Jun '25: Promoters 49.9%, Public 50.1%.Sep '25: Promoters 50.0%, Public 50.0%.Dec '25: Promoters 50.0%, Public 50.0%.Mar '26: Promoters 50.0%, Public 50.0%.Jun '26: Promoters 50.0%, Public 50.0%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Rajan Malhotra +0.80 pp 3.34% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Ishita Drugs & Industries Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Umang Financial Services Limited | 9.94% | unchanged |
| Abha Agrawal | 8.39% | unchanged |
| Sumit Agrawal | 7.76% | unchanged |
| Krishn Sumit Agrawal | 4.68% | unchanged |
| Shri Jagdish Agrawal | 4.41% | unchanged |
| Ishita Overseas Private Limited | 4.35% | unchanged |
| Divya Sumit Agrawal | 3.48% | unchanged |
| Rajan Malhotra | 3.34% | +0.80 pp |
| Agrawal Jagdishprasad G | 2.84% | unchanged |
| Mahendra Girdharilal Wadhwani | 2.15% | unchanged |
| Vikkramm Chandirramani | 1.36% | unchanged |
| Varlika Sumit Agrawal | 1.34% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Ishita Drugs & Industries Ltd.
Guides on how to read this kind of business and the numbers that matter.